Substance / Medication

Ropinirole hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Sustained release microspheres of ropinirole hydrochloride: effect of process parameters.
Avachat Amelia M, Bornare Pralhad N, Dash Rakesh R · Acta Pharm · 2011
PMID: 22202196Observational
Retracted: Clinical Observation of Ropinirole Hydrochloride in the Treatment of Parkinson's Disease.
Methods In Medicine Computational And Mathematical · Comput Math Methods Med · 2023
PMID: 37475931OtherFull text (PMC)
PEO--PCL/Tween 80/cyclodextrin systems: from bioinspired fabrication to possible nasal administration of ropinirole hydrochloride.
Saitani Elmina-Marina, Pippa Natassa, Perinelli Diego Romano et al. · J Mater Chem B · 2024
PMID: 38804576Preclinical
Fabricating Polymer/Surfactant/Cyclodextrin Hybrid Particles for Possible Nose-to-Brain Delivery of Ropinirole Hydrochloride: In Vitro and Ex Vivo Evaluation.
Saitani Elmina-Marina, Pippa Natassa, Perinelli Diego Romano et al. · Int J Mol Sci · 2024
PMID: 38256239PreclinicalFull text (PMC)
Biocompatible mucoadhesive nanoparticles for brain targeting of ropinirole hydrochloride: Formulations, radiolabeling and biodistribution.
Darwish Wael M, Bayoumi Noha A, Ebeid Nahed H · Biopolymers · 2022
PMID: 35403210Preclinical
Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety.
Chatzitaki Aikaterini-Theodora, Jesus Sandra, Karavasili Christina et al. · Int J Pharm · 2020
PMID: 32818538Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ropinirole hydrochloride (substance)
SNOMED CT
108474004
UMLS CUI
C0771840

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.